Abstract
Diabetes mellitus is a group of diseases characterized by chronic hyperglycemia. Women who develops hyperglycemia for the first time during pregnancy receive the diagnosis gestational diabetes mellitus (GDM). Presently, there is no consensus about the diagnostic criteria for GDM. A majority of these women subsequently develop postpartum overt diabetes making it important to identify these patients as early as possible. In this study we investigated if plasma levels of the interleukin-1 receptor antagonist (IL-1Ra), an endogenous inhibitor of IL-1 signaling, can be used as a complementary biomarker for diagnosing GDM and predicting postpartum development of overt diabetes mellitus. Patients participating in this study (n = 227) were diagnosed with their first GDM 2004–2013 at Lund University Hospital, Lund, Sweden. Healthy pregnant volunteers (n = 156) were recruited from women’s welfare centers in the same region 2014–2015. Levels of IL-1Ra and C-peptide were analyzed in ethylenediaminetetraacetic acid (EDTA)-plasma or serum using enzyme linked immunosorbent assay (ELISA). GDM patients had significantly lower levels of IL-1Ra than the control group (p = 0.012). In addition, GDM patients that had developed impaired glucose tolerance (IGT) or type 2 diabetes mellitus postpartum had significantly lower levels of IL-1Ra, and significantly higher levels of C-peptide than GDM patients that had not developed diabetes mellitus postpartum (p = 0.023) and (p = 0.0011) respectively. An inverse correlation was found between IL-1Ra and serum C-peptide levels in the control group (rs = -0.31 p = 0.0001). Our results show that IL-1Ra might be included in a future panel of biomarkers, both for diagnosing GDM to complement blood glucose, and also identifying GDM patients that are at risk of developing type 2 diabetes mellitus postpartum. However, the ROC curve analysis provided a sensitivity of 52.2% and specificity of 67.1%, which nonetheless may not be sufficient enough to use IL-1Ra as a sole biomarker.
Introduction
Diabetes mellitus is a group of diseases characterized by hyperglycemia due to lack of insulin or disturbances in insulin signaling. The most common forms of diabetes are type 1 and type 2 diabetes mellitus. Type 1 diabetes mellitus is an autoimmune disease that results in an insulin deficiency, whereas type 2 diabetes mellitus is characterized by peripheral insulin resistance frequently in combination with a dysfunctional insulin production. [1]
During pregnancy, the metabolic state undergoes a substantial change, which also affects insulin action and sensitivity. During the second half of pregnancy this affect is increased with resulting insulin resistance and subsequent hyperglycemia. In most cases the body is able to compensate for this with increased insulin secretion and most cases resolves with delivery. [2, 3]
Gestational diabetes mellitus (GDM) is defined by the American diabetes association as glucose intolerance first diagnosed during pregnancy. GDM affects approximately 1-14% of all pregnancies depending on the ethnicity of the patient group studied and diagnostic criteria used [1]. In southern Sweden the prevalence of GDM is 2.2% [4]. Patients with GDM are hyperglycemic and suffer from increased insulin resistance, similar to patients with type 2 diabetes mellitus [5]. Many patients with GDM develop impaired glucose tolerance (IGT) or type 2 diabetes mellitus postpartum [6]. The reported incidence of type 2 diabetes postpartum varies between 2.6–70% [7].
Measuring plasma glucose has long been the gold standard for diagnosing GDM, commonly determined with fasting plasma glucose (FPG) and oral glucose tolerance tests (OGTT). However, the diagnostic criteria for GDM varies in different countries, and there is a lack of consensus concerning the plasma glucose threshold level. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was designed to evaluate hyperglycemia during pregnancy in relation to the risk of adverse perinatal outcomes [8]. The HAPO study found a linear increase in risk of adverse outcomes with increasing plasma glucose, without a clear cut-off level [9]. Based on the results of the HAPO study the International Association of Diabetes and Pregnancy Study Group (IADPSG) delivered new diagnostic guidelines for GDM [10]. The new guidelines resulted in an overall prevalence of GDM of 17.8% in the HAPO patient material [11], an increase by almost 50% [12]. However, the new guidelines have been criticized by others [12, 13], and consensus is yet to be established.
Despite that GDM is acknowledged by researchers to be a complex disorder, focus for establishing diagnostic criteria has solely been on hyperglycemia, while other factors that promote the pathogenesis of the disease have received less attention. Soluble biomarkers are successfully used in the diagnosis of many diseases including type 1 diabetes mellitus [14, 15], and could together with blood glucose improve the diagnosis of GDM.
In addition, since GDM during pregnancy greatly increases the risk of postpartum development of overt diabetes mellitus [16] it is important to find biomarkers or clinical parameters that can predict postpartum development of diabetes mellitus already during pregnancy, in order to be able to provide early treatment.
The interleukin-1 (IL-1) receptor antagonist, IL-1Ra, is an endogenous IL-1 inhibitor and binds to the IL-1 receptor type 1 (IL-1RI), but it fails to induce intracellular signaling, and thus serves as a competitive inhibitor of IL-1 [17].
The recombinant IL-1Ra drug Anakinra has been shown to improve plasma glucose levels and β-cell function but not insulin resistance in patients with type 2 diabetes mellitus [18]. Subsequently it seems that IL-1Ra has positive effects on β-cell function and insulin secretion, but its effect in other tissues appears to be less beneficial. Interestingly, a knock-down study of IL-1Ra in obese insulin resistant mice showed reduced insulin resistance in the liver, and also reduced body weight and blood glucose levels [19].
The aims of this study were to investigate if levels of IL-1Ra can be used as a complementary biomarker for diagnosing GDM and predicting the development of overt diabetes mellitus postpartum.
Materials and Methods
Participants
First-time GDM patients (n = 227) diagnosed at Lund University Hospital, Lund, Sweden, between 2004 and 2013 were included in the study. GDM was diagnosed with a 2 hour 75g OGTT following overnight fast. The diagnostic criteria for GDM was a plasma glucose value exceeding 10 mmol/L. Some of the women had developed IGT (n = 28) or type 2 diabetes mellitus (n = 34) within 6 years (in median 3 years) after clinical onset while the majority remained normoglycemic (n = 165). A control group (n = 156) of pregnant volunteers without a family history of diabetes was recruited at women’s welfare centers in the same region (Malmö (Lindängen), Dalby and Staffanstorp) in 2014–2015. Body mass index (BMI) was available for the majority of GDM patients (n = 215) and controls (n = 147). Blood samples were drawn into ethylenediaminetetraacetic acid (EDTA)-plasma and serum tubes in the 12th week of gestation from healthy controls (n = 156) and from women with a family history of diabetes mellitus or a BMI>30 (n = 139). Samples from patients without a family history of diabetes mellitus and BMI<30 were taken in the 28th week of gestation (n = 88). Samples were sent to the laboratory by ordinary mail and stored at -70°C until time of analysis except for C-peptide which was analyzed immediately. This study was approved by the Regional Ethical Review Board in Lund (Regionala etikprövningsnämnden i Lund; 2014/383, 2014/744), and performed in accordance with the Declaration of Helsinki. All participants were given oral and written information about the study before giving written informed consent.
IL-1Ra analysis
IL-1Ra was analyzed in EDTA-plasma using a commercially available enzyme linked immunosorbent assay (ELISA) kit (R&D systems, Minneapolis, MN, USA) according to the manufacturers' instructions, optimized for human plasma. Samples were diluted 1:5, or 1:20 if the concentration at dilution 1:5 was found to exceed the highest standard concentration, and analyzed in duplicates. The absorbance was measured at 450 nm and 405 nm in a FLOUstar Optima ELISA plate reader (BMG Labtech Gmbh, Ortenberg, Germany). The highest concentration in the 7-point standard dilution series was changed from 2500 pg/mL to 5000 pg/mL, since the lowest concentration was undetectable by the plate reader. The inter- and intra-coefficient of variation were 18.9% and 20.0%, respectively. Control and patient samples were alternated on each ELISA plate in order to minimize the effect of inter-variation.
C-peptide analysis
C-peptide was analyzed in serum using a commercially available ELISA kit (Mercodia AB, Uppsala, Sweden) according to the manufacturers’ instructions. The detection limit of the assay was 25 pmol/L. The intra-assay and inter-assay coefficient of variation were 2.9–4.8% and 0.6–4.8%, respectively.
Statistical analyses
Normal distribution was estimated using the D'Agostino-Pearson test for normality. Normally distributed data is presented as mean ± standard deviation (SD), and non-normally distributed data as median [interquartile range]. Depending on the distribution, t-test or the Mann-Whitney U test were performed to test for differences in mean or mean rank respectively between two groups. In order to test for differences in more than two groups, analysis of variance (ANOVA) or the Kruskal-Wallis H test was performed depending on the distribution of the parameters analyzed. The χ²-test was used to determine differences in family history of diabetes mellitus between GDM patients and controls. The Spearman rank-correlation test was performed to investigate correlations in continuous variables. The precision of the IL-1Ra ELISA as a diagnostic and prognostic tool was evaluated using a receiver operating characteristic (ROC) curve analysis. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using MedCalc (MedCalc Software, Ostend, Belgium) for Windows® v12.7.0.0.
Results
Clinical and biochemical data for controls and women with GDM and/or postpartum development of IGT or type 2 diabetes mellitus are presented in Table 1. The p-values given are calculated with ANOVA, the Kruskal-Wallis H test or χ²-test depending on the variable analyzed.
Table 1. Clinical and biochemical data for controls and GDM patients with and without postpartum IGT or type 2 diabetes mellitus.
| Controls (n = 156) | GDM without postpartum diabetes (n = 158) | GDM with postpartum IGT/T2DM (n = 69) | p-value | |
|---|---|---|---|---|
| Age (years) | 29.8 ± 5.3 | 32.1 ± 5.3 | 32.0 ± 6.0 | <0.001 |
| Body mass index (kg/m2) | 25.4 [23.1–28.9] | 26.3 [23.5–31.6] | 28.3 [23.1–32.9] | 0.053 |
| Family history of diabetes (yes/no) | 47/109 | 60/98 | 34/35 | 0.021 |
| C-peptide (nmol/L) | 0.47 [0.31–0.74] | 0.93 [0.53–1.61] | 1.30 [0.97–1.93] | <0.000001 |
| IL-1Ra (pg/mL) | 2902 [1074-6030] | 2285 [491–5826] | 883 [0–4047] | 0.0033 |
Values are presented as mean ± SD or median [interquartile range]
Lower levels of IL-1Ra in GDM patients
Women with GDM had significantly lower plasma levels of IL-1Ra (1964 [306–5276] pg/mL) compared to pregnant controls (2902 [1074-6030] pg/mL; p = 0.012). Performing a ROC curve analysis on plasma levels of IL-1Ra as a possible diagnostic tool for GDM generated a criterion of ≤820 pg/ml. Applying this criterion resulted in a sensitivity of 37.9% and a specificity of 79.5%.
In addition, patients with postpartum development of IGT or type 2 diabetes mellitus had significantly lower levels of IL-1Ra than GDM patients that had not developed any glucose intolerance postpartum (883 [0–4047] pg/mL and 2285 [491–5826] pg/mL respectively; p = 0.023). A ROC curve analysis of IL-1Ra as a possible prognostic tool for postpartum development yielded a criterion of ≤889pg/ml with a sensitivity and specificity of 52.2% and 67.1%, respectively. There was no statistically significant difference in IL-1Ra or C-peptide levels between samples taken from patients in the 12th or 28th week of gestation (p = 0.21 and p = 0.99).
Increased levels of C-peptide in GDM patients
The controls had significantly lower levels of C-peptide (0.47 [0.31–0.74] nmol/L) than both GDM patients without postpartum glucose intolerance 0.93 [0.53–1.61] nmol/L) and GDM patients with postpartum development 1.30 [0.97–1.93] nmol/L; p<0.000001). There was also a statistically significant difference between women with and without postpartum development (p = 0.0011).
Correlation between C-peptide and IL-1Ra
An inverse correlation between C-peptide and IL-1Ra levels was found the control group (rs = -0.31, p = 0.0001), but not in the group of GDM patients (rs = -0.05, p = 0.49). No significant correlation was found when subdividing patients at week 12 (rs = -0.04, p = 0.61) and at week 28 (rs = -0.06, p = 0.59). We could not observe any correlation between levels of IL-1Ra and age or BMI in any of the groups.
The data set containing raw data of IL-1Ra, C-peptide, gestational age and postpartum development is provided as Supporting Information (S1 Data set).
Discussion
In this study we showed that GDM patients have significantly lower levels of IL-1Ra in plasma than healthy pregnant controls. This suggest that since patients with GDM have lower levels of the anti-inflammatory IL-1Ra, the biological effect of IL-1 is enhanced and thus promote the inflammatory process associated with GDM. As mentioned above, there is a need for better diagnostic markers for GDM. One possibility is to put together a panel of biomarkers used to screen for GDM. However, the ROC curve analysis of the IL-1Ra ELISA as a diagnostic tool resulted in a relatively low sensitivity and specificity. Therefore, IL-1Ra might not be a fully satisfactory biomarker on its own, but it may however play an important role in a future panel of biomarkers.
We also showed that women with GDM that developed IGT or type 2 diabetes mellitus postpartum had significantly lower levels of IL-1Ra compared to GDM patients that did not develop any postpartum glucose intolerance. The ROC curve analysis provided a sensitivity of 52.2% and specificity of 67.1%, which nonetheless may not be sufficient enough to use IL-1Ra as a sole biomarker. Therefore, we suggest that IL-1Ra could be included in a panel of biomarkers for the prediction of postpartum development of IGT or type 2 diabetes mellitus in GDM patients already during pregnancy. It is important to identify the GDM patients that will go on to develop IGT or type 2 diabetes mellitus postpartum as early as possible to be able to provide better treatment.
Levels of C-peptide were higher in patients with postpartum development of IGT or type 2 diabetes mellitus than in patients without postpartum glucose intolerance, indicative of increased insulin resistance and increased insulin secretion in the former group. In a previous study no difference in C-peptide levels was found between patients with or without postpartum development of diabetes mellitus [20]. However, that study included patients with both type 1 and type 2 diabetes mellitus.
An inverse correlation between C-peptide and IL-1Ra levels was also found, but only in the control group. Since all controls were collected in week 12 we wanted to exclude the possibility of bias due to gestational age. But no correlations were found in patients at week 12 and at week 28 which suggests that in normal pregnancy IL-1Ra promotes normal β-cell function and maintaining normal C-peptide levels. It is well known that high glucose levels are toxic for β-cells, via the induction of IL-1β. One study has reported that this glucotoxicity can be prevented by IL-1Ra thus restoring β-cell function [21]. This is well in accordance with our findings, where the controls have higher levels of IL-1Ra and also normal β-cell function as estimated with C-peptide values, whereas GDM patients have lower levels of IL-1Ra in combination with a β-cell dysfunction and generally high C-peptide values.
A strength with the study is that it is conducted in a region of Sweden where there is a screening program for GDM that includes all pregnant women performing an OGTT. Thus, all patients with GDM in the region are represented. In addition, the controls in this study are also pregnant women, which increases the reliability of our findings. Limitations of the study is that some C-peptide levels were taken fasting and some were taken non-fasting at the different women’s welfare centers. Nevertheless, this includes both GDM patients and controls. Also, the samples were taken at different gestational age, all samples from controls were taken in week 12, whereas samples from GDM patients were taken either in week 12 or 28. However, the majority of samples from the GDM patients were taken in week 12 and most importantly, there was no difference in levels of IL-1Ra or C-peptide between samples taken from patients in week 12 or 28. Furthermore, the GDM patients and control group were not matched for age. However, the difference in mean age was only 2.3 years, there are no studies that have shown that this age difference affects levels of IL-1Ra.
To our knowledge no other reports have been published concerning IL-1Ra in GDM patients, but studies have been made in patients suffering from other diseases, including metabolic syndrome and type 2 diabetes mellitus. In one of these studies IL-1Ra was analyzed in 12,885 controls and patients with metabolic syndrome or diabetes mellitus in Finland [22]. The reported values of IL-1Ra in all groups were much lower than levels found in our study even though the same ELISA kit from R&D Systems is used. However, it is not stated in the study if the samples of use were serum or plasma. It is unclear if this reflects that levels of IL-1Ra are increased in pregnancy.
In future studies plasma levels of soluble IL-1 receptor type II (IL-1RII) may be analyzed, to further investigate the role of IL-1 and inhibitors of IL-1 signaling in GDM patients. IL-1RII is a decoy receptor for IL-1, as it lacks the intracellular TIR domain that mediates signaling [23]. In addition, the correlation between IL-1Ra and C-peptide levels in the control group could be further investigated in a larger group of participants to be able to decipher the role of IL-1Ra in β-cell function.
In conclusion, this is the first study to show that GDM patients have significantly lower plasma levels of IL-1Ra than healthy pregnant women. Further, we show that GDM patients with postpartum development of IGT or type 2 diabetes mellitus have ever lower levels of IL-1Ra. In addition, we showed that GDM patients have significantly higher C-peptide levels than healthy controls and that GDM patients with postpartum development of IGT or type 2 diabetes mellitus have in turn even higher C-peptide levels. Our results show that IL-1Ra might be included in a future panel of biomarkers, both for diagnosing GDM to complement blood glucose, and also identifying GDM patients that are at risk of developing type 2 diabetes mellitus postpartum. However, the ROC curve analysis provided a sensitivity of 52.2% and specificity of 67.1%, which nonetheless may not be sufficient enough to use IL-1Ra as a sole biomarker.
Supporting Information
(XLS)
Acknowledgments
We would like to thank Mrs. Birgitte Ekholm for excellent technical assistance and nurses and midwifes at the women´s welfare centers in Lindängen, Dalby and Paletten in Staffanstorp for assisting in the collection of healthy pregnant controls.
Data Availability
Due to ethical restrictions, the authors must ensure that the integrity of the participants in this study is preserved. Since it is clearly stated in the paper from which health care centers and hospitals the authors’ have recruited the controls and patients, the authors cannot provide any clinical data (age, BMI, family history of diabetes) that enables possible identification of the participants. The authors can, however, provide a minimal data set of IL-1Ra and C-peptide levels in each group, which could be of use to research laboratories trying to confirm the results from this study. The authors also believe that IL-1Ra and C-peptide are the only data required to replicate the results found in this study. The corresponding author of this paper is available for inquiries regarding all the data if required. The minimal data set supporting this study is provided as a Supporting Information file.
Funding Statement
MH received funding for this study from Sydvästra Skånes Diabetesförening (grant number 1040390) (web page: http://www.diabetes.se/ Foreningar/Skane-lan/Lokalforeningar/Sydvastra-Skanes-Diabetesforening/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–90. Epub 2013/12/21. 10.2337/dc14-S081 . [DOI] [PubMed] [Google Scholar]
- 2.Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nature reviews Endocrinology. 2012;8(11):639–49. Epub 2012/07/04. 10.1038/nrendo.2012.96 ; Central PMCID: PMCPMC4404707. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Haller-Kikkatalo K, Uibo R. Clinical Recommendations for the Use of Islet Cell Autoantibodies to Distinguish Autoimmune and Non-Autoimmune Gestational Diabetes. Clin Rev Allergy Immunol. 2014. 10.1007/s12016-014-8461-8 . [DOI] [PubMed] [Google Scholar]
- 4.Ignell C, Claesson R, Anderberg E, Berntorp K. Trends in the prevalence of gestational diabetes mellitus in southern Sweden, 2003–2012. Acta Obstet Gynecol Scand. 2014;93(4):420–4. 10.1111/aogs.12340 . [DOI] [PubMed] [Google Scholar]
- 5.Ryan EA, O'Sullivan MJ, Skyler JS. Insulin Action During Pregnancy: Studies with the Euglycemic Clamp Technique. Diabetes. 1985;34(4):380–9. 10.2337/diab.34.4.380 [DOI] [PubMed] [Google Scholar]
- 6.Capula C, Chiefari E, Vero A, Foti DP, Brunetti A, Vero R. Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2014;105(2):223–30. 10.1016/j.diabres.2014.05.008 . [DOI] [PubMed] [Google Scholar]
- 7.Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25(10):1862–8. . [DOI] [PubMed] [Google Scholar]
- 8.Hapo Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet. 2002;78(1):69–77. 10.1016/S0020-7292(02)00092-9. . [DOI] [PubMed] [Google Scholar]
- 9.Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002. 10.1056/NEJMoa0707943 . [DOI] [PubMed] [Google Scholar]
- 10.International Association of Diabetes Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82. 10.2337/dc09-1848 ; Central PMCID: PMC2827530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012;35(3):526–8. 10.2337/dc11-1641 ; Central PMCID: PMC3322716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ryan EA. Diagnosing gestational diabetes. Diabetologia. 2011;54(3):480–6. 10.1007/s00125-010-2005-4 ; Central PMCID: PMC3034033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Long H. Diagnosing gestational diabetes: can expert opinions replace scientific evidence? Diabetologia. 2011;54(9):2211–3. 10.1007/s00125-011-2228-z . [DOI] [PubMed] [Google Scholar]
- 14.Parrinello C, Selvin E. Beyond HbA1c and Glucose: the Role of Nontraditional Glycemic Markers in Diabetes Diagnosis, Prognosis, and Management. Current Diabetes Reports. 2014;14(11):1–10. 10.1007/s11892-014-0548-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bonifacio E. Predicting Type 1 Diabetes Using Biomarkers. Diabetes Care. 2015;38(6):989–96. 10.2337/dc15-0101 [DOI] [PubMed] [Google Scholar]
- 16.Jarvela IY, Juutinen J, Koskela P, Hartikainen AL, Kulmala P, Knip M, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care. 2006;29(3):607–12. . [DOI] [PubMed] [Google Scholar]
- 17.Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991;266(16):10331–6. . [PubMed] [Google Scholar]
- 18.Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517–26. 10.1056/NEJMoa065213 . [DOI] [PubMed] [Google Scholar]
- 19.Franck N, Maris M, Nalbandian S, Talukdar S, Schenk S, Hofmann H-P, et al. Knock-Down of IL-1Ra in Obese Mice Decreases Liver Inflammation and Improves Insulin Sensitivity. PLoS ONE. 2014;9(9):e107487 10.1371/journal.pone.0107487 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Nilsson C, Hillman M, Ursing D, Strevens H, Landin-Olsson M. Clinical use of C-peptide and β-cell specific autoantibodies during gestational diabetes mellitus. Practical Diabetes. 2012;29(3):105–8. 10.1002/pdi.1668 [DOI] [Google Scholar]
- 21.Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110(6):851–60. 10.1172/JCI15318 ; Central PMCID: PMC151125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Luotola K, Pietilä A, Zeller T, Moilanen L, Kähönen M, Nieminen MS, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. Journal of Internal Medicine. 2011;269(3):322–32. 10.1111/j.1365-2796.2010.02294.x [DOI] [PubMed] [Google Scholar]
- 23.Peters VA, Joesting JJ, Freund GG. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain Behav Immun. 2013;32:1–8. 10.1016/j.bbi.2012.11.006 ; Central PMCID: PMC3610842. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
(XLS)
Data Availability Statement
Due to ethical restrictions, the authors must ensure that the integrity of the participants in this study is preserved. Since it is clearly stated in the paper from which health care centers and hospitals the authors’ have recruited the controls and patients, the authors cannot provide any clinical data (age, BMI, family history of diabetes) that enables possible identification of the participants. The authors can, however, provide a minimal data set of IL-1Ra and C-peptide levels in each group, which could be of use to research laboratories trying to confirm the results from this study. The authors also believe that IL-1Ra and C-peptide are the only data required to replicate the results found in this study. The corresponding author of this paper is available for inquiries regarding all the data if required. The minimal data set supporting this study is provided as a Supporting Information file.